Jane Street
SGMT icon

Jane Street’s Sagimet Biosciences SGMT Stock Holding History

Jane Street’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,400
Closed -$216K – 11666
2025
Q2 		$216K Buy
+28,400
New +$120K ﹤0.01% 8415

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jane Street's SGMT Position: Q1 2026 in Review

Jane Street reduced its Sagimet Biosciences (SGMT) stake by 81% in Q1 2026, selling an estimated $419K and leaving 17,187 shares worth $89.8K. The position accounts for ﹤0.01% of the portfolio, ranked #10699.

Jane Street first reported a position in SGMT in Q1 2024 and has held it in 8 quarters since. The position peaked at $547K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Jane Street held 17,187 shares of Sagimet Biosciences worth $89.8K as of Q1 2026.
  • Jane Street sold 75,249 Sagimet Biosciences shares in Q1 2026, an estimated $419K.
  • Sagimet Biosciences made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10699 holding.
  • Jane Street first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 8 quarters since.
  • Jane Street's Sagimet Biosciences position peaked at $547K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.